Effect of Huatan Qushi Huoxue prescription on the ADPN/AMPK/ACC signaling pathway in rats with nonalcoholic steatohepatitis

Zhao WenXia; Yan Le; Shao MingYi; Zhang LiHui

doi:10.3969/j.issn.1001-5256.2017.05.029

Issue 5

May 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(5): 932-936

PDF( 1259 KB)

Effect of Huatan Qushi Huoxue prescription on the ADPN/AMPK/ACC signaling pathway in rats with nonalcoholic steatohepatitis

DOI: 10.3969/j.issn.1001-5256.2017.05.029

Department of Splenic, Gastric, and Hepatobiliary Diseases, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Research funding:

Published Date: 2017-05-20

Abstract

Abstract

Objective To investigate the effect of Huatan Qushi Huoxue prescription on the adiponectin (ADPN) /adenosine monophosphate-activated protein kinase (AMPK) /acetyl-Co A carboxylase (ACC) signaling pathway in rats with nonalcoholic steatohepatitis (NASH) .Methods A total of 72 male Sprague-Dawley rats were randomly divided into blank group, model group, control group, and high-, middle-, and low-dose Huatan Qushi Huoxue prescription groups.All rats except those in the blank group were given high-fat diet combined with intraperitoneal injection of tetracycline to establish a rat model of NASH.At week 2 after model establishment, the Huatan Qushi Huoxue prescription groups were treated with high-, middle-, and low-dose Huatan Qushi Huoxue prescription, and polyene phosphatidylcholine (Yishanfu) capsules were given as control.At the end of the experiment, the content of free fatty acid (FFA) in liver homogenate was measured, and ELISA and RT-q PCR were used to measure the protein and mRNA expression of ADPN, adiponectin receptor-2 (AdipoR2) , AMPK, ACC, and carnitine palmitoyltransferase-1 (CPT-1) in liver tissue.An analysis of variance was used for comparison of data between multiple groups;the least significant difference t-test was used for comparison of data with homogeneity of variance between two groups, and the Dunnett's T3 method was used for comparison of data with heterogeneity of variance.Results Compared with the control group, the high-dose group had significant reductions in FFA level in liver homogenate (229.07±46.62 μmol/gprot vs 382.75 ±30.93 μmol/gprot, P<0.01) and mRNA and protein expression of ACC in liver tissue (mRNA:1.66±0.04 vs 2.40±0.37, P<0.01;protein:512.20±60.70 pg/g vs 756.72±61.21 pg/g, P<0.01) , as well as significant increases in the mRNA and protein expression of ADPN (mRNA:1.53±0.31 vs 0.75±0.11, P<0.01;protein:22.23±2.75 μg/g vs 14.01±2.17 μg/g, P<0.01) , AdipoR2 (mRNA:1.38±0.33 vs 0.61±0.09, P<0.01;protein:128.41±10.46 ng/g vs 94.62±6.88 ng/g, P<0.01) , AMPK (mRNA:1.43±0.39 vs 0.78±0.04, P<0.01;protein:1353.79±59.52 μg/g vs 1107.19±56.78 μg/g, P<0.01) , and CPT-1 (mRNA:1.39±0.31 vs 0.52±0.04, P<0.01;protein:175.54±9.91 U/g vs 128.74±12.74 U/g, P<0.01) .Conclusion Huatan Qushi Huoxue prescription can effectively activate the ADPN/AMPK/ACC signaling pathway, which may affect the β oxidation and synthesis of fatty acids and reduce fat deposition in hepatocytes.
- nonalcoholic steatohepatitis,
- Huata Qushi Huoxue recipe,
- adiponectin,
- amp-activated protein kinase,
- acetyl-CoA carboxylase

FullText(HTML)

References(15)

References

[1]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会肪肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[2]YOUNOSSI ZM, MANN PK, WYMER M.Reply to the letter to the editor:global epidemiology of non-alcoholic fatty liver disease (NAFLD) [J].Hepatology, 2016, 64 (4) :1391-1393.

[3]BUECHLER C, WANNINGER J, NEUMEIER M.Adiponectin, a key adipokine in obesity related liver diseases[J].World J Gastroenterol, 2011, 17 (23) :2801-2811.

[4]LIANG HW, ZHAO WX.Effect of Xiaozhihugan Capsule on patients with non-alcoholi steatohepatitis, adiponectin and insulin resistance[J].Chin J Integr Tradit West Med Liver Dis, 2015, 25 (5) :264-266. (in Chinese) 梁浩卫, 赵文霞.消脂护肝胶囊对非酒精性脂肪性肝炎患者脂联素和胰岛素抵抗的影响[J].中西医结合肝病杂志, 2015, 25 (5) :264-266.

[5]ZHAO WX, YAN L, DUAN RZ.Effects of Huatan Qushi Huoxue Formula on hepatic pathological changes in nonalcoholic steatohepatitis model rats[J].J Tradit Chin Med, 2014, 55 (14) :1223-1226. (in Chinese) 赵文霞, 闫乐, 段荣章.化痰祛湿活血方对非酒精性脂肪性肝炎大鼠肝脏病理的影响[J].中医杂志, 2014, 55 (14) :1223-1226.

[6]ZHAO WX, YAN L, DUAN RZ.Effects of Huatan Qushi Huoxue Recipe on the expression of adiponectin and adiponectin receptors in rats with nonalcoholic steatohepatitis[J].China J Tradit Chin Med Pharma, 2014, 29 (9) :2975-2977. (in Chinese) 赵文霞, 闫乐, 段荣章.化痰祛湿活血方对非酒精性脂肪性肝炎大鼠脂联素及其受体的干预研究[J].中华中医药杂志, 2014, 29 (9) :2975-2977.

[7]ZHAO WX, LIU XT, YAN L.The impact of Ze Shen formulas particles on ADPN/AMPK signaling pathway in LO2 Steatosis[J].Chin Hepatol, 2014, 19 (6) :448-450. (in Chinese) 赵文霞, 刘雪涛, 闫乐.泽参颗粒对脂肪变LO2细胞ADPN/AMPK信号通路的影响[J].肝脏, 2014, 19 (6) :448-450.

[8]PAN Q, FAN JG.Animal model of high fat diet-induced nonalcoholic fatty liver disease[J].Int J Dig Dis, 2009, 29 (4) :255-257. (in Chinese) 潘勤, 范建高.高脂饮食诱导非酒精性脂肪性肝病动物模型的研究进展[J].国际消化病杂志, 2009, 29 (4) :255-257.

[9]SHEN C, GAO J, ZHAO CY.Animal models of non-alcoholic fatty liver disease:recent advances[J].World Chin J Dig, 2009, 17 (33) :3414-3419. (in Chinese) 申川, 高健, 赵彩彦.非酒精性脂肪性肝病动物模型研究进展[J].世界华人消化杂志, 2009, 17 (33) :3414-3419.

[10]NOORI M, JAFARI B, HEKMATDOOST A.Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation[J].J Sci Food Agric, 2016.[Epub ahead of print]

[11]TILG H.Adipocytokines in nonalcoholic fatty liver disease:key players regulating steatosis, inflammation and fibrosis[J].Current Pharmaceutical Design, 2010, 16 (17) :1893-1895.

[12]JUNG UJ, CHOI MS.Obesity and its metabolic complications:the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease[J].Int J Mol Sci, 2014, 15 (4) :6184-6223.

[13]FINELLI C, TARANTINO G.What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?[J].World J Gastroenterol, 2013, 19 (6) :802-812.

[14]MATSUNAMI T, SATO Y, ARIGA S, et al.Yukawa M Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model[J].Metabolism, 2011, 60 (6) :805-814.

[15]IDETA T, SHIRAKAMI Y, MIYAZAKI T, et al.The dipeptidyl peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice[J].Int J Mol Sci, 2015, 16 (12) :29207-29218.

Relative Articles

[1]	Haiyang ZHU, Jingshu CUI, Liu YANG, Mengting ZHOU, Jian TONG, Hongmei HAN. Mechanism of 1，25（OH）₂D₃ improving liver inflammation in a rat model of nonalcoholic steatohepatitis induced by choline-deficient L-amino acid-defined diet[J]. Journal of Clinical Hepatology, 2025, 41(2): 254-262. doi: 10.12449/JCH250210
[2]	Xin XU, Zhangxing CHEN. Correlation of the serum levels of adiponectin， omentin， and visfatin with the severity of acute pancreatitis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1848-1852. doi: 10.12449/JCH240920
[3]	Yijing XIN, Yiyun CHEN, Hailin YANG, Yunhui ZHUO, Dingqi ZHANG, Fengfeng ZHOU. Effect of Xuanfuhua decoction on a mouse model of nonalcoholic steatohepatitis induced by high-fat, high-fructose, and high-cholesterol diet[J]. Journal of Clinical Hepatology, 2023, 39(6): 1340-1350. doi: 10.3969/j.issn.1001-5256.2023.06.014
[4]	Enrui XIA, Gege TIAN, Suyan ZHANG, Shunzhen ZHANG. Effect of Quzhi Ruangan prescription on the farnesoid X receptor-fibroblast growth factor 19 pathway in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1069-1074. doi: 10.3969/j.issn.1001-5256.2022.05.018
[5]	Yingshuo HUANG, Wei WEI, Xiaofei TONG, Yameng SUN, Jianxiong ZHANG, Ruihua DONG, Jidong JIA, Hong YOU. Clinical trial protocols of new drugs for nonalcoholic steatohepatitis: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(4): 798-804. doi: 10.3969/j.issn.1001-5256.2022.04.012
[6]	Sutong LIU, Lihui ZHANG, Yajiao GU, Minghao LIU, Min GUO, Chenlu ZHAO, Wenxia ZHAO. Effect of Huatan Qushi Huoxue prescription on the ultrastructure of hepatocyte mitochondria in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1780-1783. doi: 10.3969/j.issn.1001-5256.2022.08.012
[7]	Ziming AN, Qin FENG. Magnetic resonance imaging-proton density fat fraction: A potential surrogate endpoint for nonalcoholic steatohepatitis clinical trials[J]. Journal of Clinical Hepatology, 2021, 37(6): 1445-1448. doi: 10.3969/j.issn.1001-5256.2021.06.047
[8]	Song QingLian, Tan YuE, Liu JingJing, Yuan BeiBei, Li Min, He LiQin, Dai GuangRong. Establishment of a rat model of nonalcoholic steatohepatitis and histopathological changes of the pancreas and the kidney[J]. Journal of Clinical Hepatology, 2020, 36(1): 140-144. doi: 10.3969/j.issn.1001-5256.2020.01.031
[9]	XU Zhen, LIU ShouSheng, TAN Jie, SUN BaoKai, DU ShuiXian, XIN YongNing, XUAN ShiYing. Expression and significance of leptin and adiponectin in serum of patients with nonalcoholic fatty liver disease and coronary heart disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2478-2483. doi: 10.3969/j.issn.1001-5256.2020.11.016
[10]	Zhang LiHui, Zhang JianBo, Zhao WenXia. Effect of Huatan Qushi Huoxue prescription on the key proteins of the ADPN/PI3K/Akt signaling pathway in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 835-839. doi: 10.3969/j.issn.1001-5256.2020.04.025
[11]	Huang Lei, Zhao XianLin, Wang MingHao, Wang XiaoXiang. Role of adenosine monophosphate-activated protein kinase in acute pancreatitis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2365-2368. doi: 10.3969/j.issn.1001-5256.2019.10.052
[12]	Zhou QingLi, Xu ZhenYuan, Zhang SuYan, Shi AnHua, Zhang ShunZhen. The role of the NOD-like receptor family, pyrin domain-containing protein 3 inflammasome in nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1380-1383. doi: 10.3969/j.issn.1001-5256.2019.06.045
[13]	Hu Ying, Li LiangPing. Serological noninvasive diagnosis of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2018, 34(9): 2004-2007. doi: 10.3969/j.issn.1001-5256.2018.09.037
[14]	Jiang Yu, Hu JuLong, Ma JiaLi, Li Ping, Zhou YuLing, Liang XiuXia, Ai ZhengLin, Yao ShuKun. Antioxidant effect of berberine in a rat model of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1273-1276. doi: 10.3969/j.issn.1001-5256.2018.06.028
[15]	Zhao Bin, Ma ZhenQi. Serum levels of adiponectin and ferritin and their clinical significance in patients with nonalcoholic fatty liver in Qinghai,China[J]. Journal of Clinical Hepatology, 2016, 32(10): 1955-1958. doi: 10.3969/j.issn.1001-5256.2016.10.028
[16]	Peng Hong, Yang Jian, Mai RunZhang, Chen HongTao. Relationship between serum adiponectin level and metabolic indices in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(4): 354-356. doi: 10.3969/j.issn.1001-5256.2014.04.016
[17]	Wang MeiJuan, Ma Hong. Role of adiponectin in liver fibrogenesis:progress in basic and clinical research[J]. Journal of Clinical Hepatology, 2011, 27(3): 321-324.
[18]	Zhang GuiLi, Li Qiang, Li YouSheng, Tan LiJie, Zhang Hong, Liu ShiPing, Fan YanJu, Zhou ShuFang. The relation between serum adiponectin levels and liver function correlated factors in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2010, 26(2): 184-186.
[19]	Xu LaMei, Sun DanLi, Zhang YuShu, Zhang ZhenYu, Yuan Jie, Du TongXin. The clinical significance of adiponectin expression and its diagnostic value combined with liver function tests and liver/spleen CT value in Non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2010, 26(2): 170-172.
[20]	Xu Hui, Wen QinSheng, Wang XuXia, Zhang YaFei, Li Jun, Gu BingQuan. The effect of cimetidine on the blood sugar, serum insulin and other indexes in NASH rats[J]. Journal of Clinical Hepatology, 2007, 23(2): 112-114.

Supplements(0)

Cited By

Cited by

Periodical cited type(18)

1.	罗容，吕一航，李丰源，田源，杨艳，宋一男，王蓓蓓，王维. 非酒精性脂肪性肝炎痰瘀互结证候与脂毒性关系探析. 亚太传统医药. 2023(08): 194-197 .
2.	顾亚娇，张丽慧，张剑波，赵文霞. 基于网络药理学探讨化痰祛湿活血方治疗非酒精性脂肪性肝炎作用机制及实验验证. 中西医结合肝病杂志. 2022(03): 260-265 .
3.	费景兰，张峰，陈茜，赵晨露，刘素彤，赵文霞. 虎符铜砭刮痧联合化痰祛湿活血方治疗非酒精性脂肪性肝病. 中西医结合肝病杂志. 2022(04): 319-322 .
4.	左剑雨，张鑫，宋星星，韩东洋，罗荣荣，徐文镐，陈磊，石艳，曹雅洁，李珣. GnIH对雄性SD大鼠肝脏脂代谢的影响及机制研究. 畜牧与兽医. 2022(07): 54-58 .
5.	张亮，刘鸣昊，赵文霞，刘全忠. 基于中医“痰湿瘀”理论探讨KCs细胞焦亡与代谢相关脂肪性肝病的关系. 中医药学报. 2022(10): 16-20 .
6.	刘晓彦，马素平，张丽慧，赵文霞. 赵文霞教授“四辨”“四分”论治非酒精性脂肪性肝病经验. 中西医结合肝病杂志. 2022(11): 964-968 .
7.	黄亚森，张振凌，刘鸣昊. LC-MS/MS法比较不同炮制饮片组成的化痰祛湿活血方中20个成分含量. 中华中医药杂志. 2022(11): 6718-6723 .
8.	田园硕，严海艺，王心意，秦雪颖，郭朋. 基于网络药理学研究柴胡治疗肝炎的分子作用机制. 中西医结合肝病杂志. 2021(04): 361-365+372 .
9.	张丽慧，马庆亮，刘鸣昊，赵文霞. 化痰祛湿活血方调控LXRα/SREBP-1c/FAS通路对慢乙肝并脂肪肝细胞模型恩替卡韦抗病毒的影响. 世界科学技术-中医药现代化. 2021(11): 4072-4080 .
10.	朱达，孙凤霞，李晓玲，徐春军，王傲然. 脂肪肝1号方治疗非酒精性脂肪性肝炎的实验研究. 中西医结合肝病杂志. 2020(04): 337-340+387 .
11.	罗冬梅，陶艳艳，刘成海. 非酒精性脂肪性肝炎发病机制和治疗研究进展. 肝脏. 2020(09): 1013-1017 .
12.	付勇刚，杨家耀. 附子理中汤对非酒精性脂肪性肝炎大鼠内毒素及其受体的影响. 世界中医药. 2020(19): 2878-2881 .
13.	朱为梅，王秀芳，杨海清，杨红玲，李学章，潘悦. 低铅对非酒精性脂肪性肝病大鼠模型肝功能和血脂的影响. 临床肝胆病杂志. 2019(04): 840-845 . 本站查看
14.	张齐，金翔宇，权海燕. 人参皂苷Compound K通过AMPK及SREBP1途径改善非酒精性脂肪肝的机制研究. 中国医院药学杂志. 2019(08): 791-795 .
15.	刘鸣昊，张丽慧，马庆亮，赵文霞. 槲皮素对非酒精性脂肪性肝炎大鼠的作用及其机制研究. 中国临床药理学杂志. 2019(20): 2597-2601 .
16.	刘君颖，张丽慧，桑锋，马庆亮，刘雪涛，赵文霞. 化痰祛湿活血方对脂肪变L02细胞促炎抑炎因子的影响. 中西医结合肝病杂志. 2019(05): 395-398 .
17.	明利平，成扬，陈建杰，平键，陈天阳. 苍菊清肝降脂方对非酒精性脂肪性肝炎大鼠肝组织SIRT1、SIRT2和SIRT3表达的影响. 河北中医. 2018(08): 1212-1216 .
18.	周红萍，杨兴鑫，庄让笑，邵益丹，席建军，廖莉，任白鹭，王萍萍，余舒莹，史婷婷. N-乙酰半胱氨酸活性炭缓释微囊对幼鼠非酒精性脂肪肝病miRNA的影响. 中国临床药理学与治疗学. 2018(03): 263-270 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (446) PDF downloads(186)

Effect of Huatan Qushi Huoxue prescription on the ADPN/AMPK/ACC signaling pathway in rats with nonalcoholic steatohepatitis

DOI: 10.3969/j.issn.1001-5256.2017.05.029